A
Annovis Bio, Inc.
ANVSCIK 0001477845NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-28.90M
Total Assets
$21.08M
Equity
$16.85M
Shares Out
28.36M
Op. Cash Flow
$-25.62M
Business
Annovis Bio, Inc. is a late-stage clinical drug platform company developing therapies for neurodegeneration, including Alzheimer’s disease and Parkinson’s disease. Its main product candidates include buntanetap (an orally administered, brain‑penetrant small molecule for chronic neurodegeneration), ANVS405 (an intravenous formulation for acute brain injury) and ANVS301 (for advanced AD). Its operations are organized around clinical development programs and pipeline segments for chronic indications, acute indications and later‑stage AD studies. The company conducts clinical trials in the U.S. and EU and plans to commercialize through third‑party partners, selling to neurologists, geriatric specialists and primary care physicians while relying on contract manufacturers.
Summary from filing dated 2025-03-21
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 25 | 20 | 39 | 17 | 8 | |
| General and administrative | 4 | 7 | 6 | 9 | 6 | |
| Total operating expenses | 30 | 27 | 45 | 26 | 15 | |
| Operating loss | −30 | −27 | −45 | −26 | −15 | |
| Interest income | 699,061 | 331,849 | 667,898 | — | — | |
| Other financing costs | — | −2 | — | — | — | |
| Change in fair value of warrants | 142,000 | 4 | −12 | — | — | |
| Total other income, net | 841,061 | 2 | −11 | 182,712 | 50,089 | |
| Net loss | −29 | −25 | −56 | −25 | −15 | |
| Basic (dollars per share) | −1.4 | −2.02 | −6.23 | −3.1 | −1.9 | |
| Diluted (dollars per share) | −1.4 | −2.31 | −6.23 | −3.1 | −1.9 | |
| Basic | 21 | 12 | 9 | 8 | 8 | |
| Diluted | 21 | 12 | 9 | 8 | 8 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 20 | 11 | 6 | 28 | 32 | |
| Prepaid expenses and other current assets | 2 | 3 | 4 | 8 | 5 | |
| Total assets | 21 | 14 | 10 | 36 | 37 | |
| Accounts payable | 3 | 2 | 1 | 4 | 2 | |
| Accrued expenses | 1 | 2 | 3 | 4 | 680,830 | |
| Total current liabilities | 4 | 4 | 4 | 8 | 3 | |
| Warrant liability | 595,000 | 737,000 | 14 | — | — | |
| Total liabilities | 4 | 5 | 18 | 8 | 3 | |
| Commitments and contingencies (Note 6) | — | — | — | — | — | |
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock - $0.0001 par value, 70,000,000 shares authorized, 27,199,139 and 14,141,521 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 2,719 | 1,414 | 1,052 | 816 | 816 | |
| Additional paid-in capital | 181 | 144 | 103 | 82 | 81 | |
| Accumulated deficit | −164 | −135 | −110 | −54 | −46 | |
| Total stockholders' equity | 17 | 9 | −8 | 28 | 35 | |
| Total liabilities and stockholders' equity | 21 | 14 | 10 | 36 | 37 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −29 | −25 | −56 | −25 | −14 | |
| Stock-based compensation expense | 2 | 4 | 5 | 9 | 5 | |
| Change in fair value of warrants | −142,000 | −4 | 12 | — | — | |
| Non-cash other financing costs | — | 2 | — | — | — | |
| Prepaid expenses and other current assets | 2 | 1 | 3 | −7 | −270,788 | |
| Accounts payable | 284,542 | 1 | −3 | 3 | 346,218 | |
| Accrued expenses | −530,154 | −1 | −751,012 | 3 | 581,916 | |
| Net cash used in operating activities | −26 | −22 | −40 | −17 | −9 | |
| Proceeds from issuance of common stock, warrants, and pre-funded warrants, net | 35 | 19 | — | — | — | |
| Proceeds from exercise of common stock options, net | 0 | 0 | 8,385 | 4,613 | 95,102 | |
| Proceeds from exercise of warrants | — | 8 | — | — | — | |
| Net cash provided by financing activities | 35 | 27 | 17 | 4,613 | 47 | |
| Net increase in cash and cash equivalents | 9 | 5 | −23 | −17 | 38 | |
| Reduction in value of warrants related to exercises | — | 9 | 606,201 | — | — | |
| Cash paid for financing costs | — | 50,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro